A Study of Degarelix in Patients With Prostate Cancer
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to see if giving Degarelix every month for 7 months then stop
treatment for 7 months (intermittent therapy) would show a reduction of negative effects of
androgen deprivation therapy by increasing the quality of life while keeping prostate
specific antigen (PSA) levels suppressed.